Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics

{
  "signal_id": "67223c4e-e382-1328-58b6-bdf0da104fa7",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-08-20T15:30:00+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/08/20/3348637/28124/en/global-dll3-targeted-therapies-market-2026-2030-profiles-amgen-zai-lab-boehringer-ingelheim-and-phanes-therapeutics.html",
    "title": "Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics",
    "excerpt": "Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The \"Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030\" has been added to ResearchAndMarkets.com's offering. Key Report Highlights: Growing Need for DLL3 Targeted Therapies DLL3 targeted therapies represent a rapidly expanding segment of precision oncology, supported by the target's high expression in small cell lung cancer and several aggressive neuroendocrine malignancies. Its tumor-selective expression has encouraged the development of multiple therapeutic approaches, including T-cell engagers, antibody-drug conjugates, multispecific antibodies, engineered cell therapies, radiopharmaceuticals and photoimmunotherapy platforms. The approval and commercial launch of Imdelltra (tarlatamab) validated DLL3 as a clinically relevant oncology target and accelerated investment in next-generation DLL3 therapies. As the first approved DLL3 targeted treatment, Imdelltra has also established an important commercial benchmark for companies developing therapies for small cell lung cancer and other DLL3-expressing tumors. The report provides a comprehensive assessment of the global DLL3 targeted therapies market, including scientific advances, therapeutic platforms, clinical development, approved therapy sales, pricing trends, regional opportunities...",
    "product": "Imdelltra",
    "summary": "Amgen's product Imdelltra reported revenue of more than USD 600 million in 2025.",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
    "confidence": 0.9,
    "product_data": {
      "name": "Imdelltra",
      "full_text": "Imdelltra",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-20T15:30:00Z",
    "effective_date": "2025-01-01",
    "article_sentence": "Imdelltra's reported revenue of more than USD 600 million in 2025 provides further evidence of the commercial potential of DLL3-directed oncology treatment.",
    "amount_normalized": 600000000
  }
}

curl https://signals.autobound.ai/v1/signals/67223c4e-e382-1328-58b6-bdf0da104fa7 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'